15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 16 firms covering ACADIA Pharmaceuticals Inc, 13 rate it Buy or better, 2 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $17.00 to $40.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $32.44 sits 25% above the current $26.01. The rating mix has stayed broadly stable, with Buy-side ratings easing from 16 to 13 over recent months. On the fundamentals, the Street sees revenue growth near 16% this year and 12% next, consensus EPS building from about $0.13 next quarter toward $0.85 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 ratings
Moderate Buy
Strong Buy00%
Buy1381%
Hold213%
Sell16%
Strong Sell00%
Based on 16 analysts giving stock ratings to ACADIA Pharmaceuticals Inc.
As of Jul, 13 of 16 firms rate ACAD a Buy (2 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
ACAD EPS & revenue forecast
EPS · NEXT QUARTER
$0.13
Range $0.08 – $0.17 · 13 analysts · -69% YoY
Next period, 13 analysts expect ACADIA Pharmaceuticals Inc to earn $0.13 a share (range $0.08 – $0.17), versus $0.42 a year earlier. Full-year consensus is $0.37, growing to $0.85 the year after.
REVENUE · NEXT QUARTER
$325.3M
Range $319.4M – $335.8M · 13 analysts · +17% YoY
Revenue is expected to reach $325.3M (range $319.4M – $335.8M), +17.0% year-over-year. Full-year consensus is $1.2B, rising to $1.4B next year.
Top analysts covering ACADIA Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACAD.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Hold
$20.00-23.1% to target
Overall win rate
61%
+ Follow
#2
Jason Butler
JMP Securities · Rank #22
Buy
$35.00+34.6% to target
Overall win rate
57%
+ Follow
#3
Ami Fadia
Needham · Rank #90
Buy
$38.00+46.1% to target
Overall win rate
46%
+ Follow
#4
Joel Beatty
Baird · Rank #111
Buy
$31.00+19.2% to target
Overall win rate
46%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$35.00+34.6% to target
Overall win rate
43%
+ Follow
ACAD stock forecast FAQ
What is ACAD's average 12-month price target?+
The 16 analysts with a live target average $32.44 for ACADIA Pharmaceuticals Inc over the next 12 months, ranging from a $40.00 high to a $17.00 low.
Is ACAD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 16 analyst ratings, 13 are Buy or Strong Buy, 2 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for ACAD?+
The Street-high target is $40.00 (UBS), and the Street-low is $17.00 (Goldman Sachs). The average of all 16 active targets is $32.44.
How many Wall Street analysts cover ACAD?+
16 analysts have an active rating on ACADIA Pharmaceuticals Inc, and 16 firms carry a live 12-month price target.
Who is the most accurate analyst covering ACAD?+
Among analysts who currently cover ACAD, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #12). Their current call is Hold with a $20.00 target.
What is ACADIA Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.13 per share (range $0.08 – $0.17) across 13 analysts. Full-year EPS is projected at $0.37, rising to $0.85 the following year.
How much revenue is ACADIA Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $325.3M (range $319.4M – $335.8M). Full-year revenue is projected at $1.2B, growing to $1.4B next year.
Have analysts been upgrading or downgrading ACAD lately?+
As of Jul, 13 of 16 firms rate ACAD a Buy (2 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACAD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
